FDA Should Track Inclusion Of Seniors In Clinical Trails More Carefully – GAO
Executive Summary
A report by the General Accountability Office concludes that the FDA rules for drug approval fail to guarantee the safety and effectiveness of drugs for seniors
You may also be interested in...
FDA’s Dubious Honor: GAO Flags Many Of Its Activities As “High Risk”
FDA's White Oak campus is still far from complete, but an extreme reading of official statements during the last few weeks might suggest that it could be closed
FDA’s Dubious Honor: GAO Flags Many Of Its Activities As “High Risk”
FDA's White Oak campus is still far from complete, but an extreme reading of official statements during the last few weeks might suggest that it could be closed
Liver Toxicity Guidance Urges Sponsors To Include Risky Patients In Trials
FDA's recent draft guidance on drug-induced liver injury recommends drug developers enroll patients with preexisting liver disease in at least Phase III clinical trials, especially if the drug might eventually be used in such patients.